Get a glimpse into our company and investor data—powered by the PitchBook Platform
M&ALATEST DEAL TYPE
$46MLATEST DEAL AMOUNT
Developer of RNAi based therapies. The company focuses on biopharmaceutical products based on RNA interference (RNAi) to prevent and treat a range of human diseases, such as inflammatory diseases and cancer.